DSIP: Research Applications
Research Applications
DSIP research spans 8+ indication categories across neurology, addiction, oncology, and gerontology:
- Sleep Regulation & Insomnia β Increases delta (slow-wave) sleep 39β54% in rabbits; 59% median increase in total sleep time in humans (25 nmol/kg IV); 7-night treatment normalized chronic insomnia.[3][4]
- Withdrawal Syndrome Treatment β 97% improvement in opiate withdrawal (n=60); 87% in alcohol withdrawal (n=47); terminated delirium tremens in 6/8 cases.[2]
- Stress Adaptation & HPA Modulation β Reduces stress-induced metabolic disorders; lowers basal corticotropin; blocks cortisol release; prevents c-fos expression during emotional stress.[18]
- Pain Management β Dose-dependent antinociceptive effect (blocked by naloxone); reduced pain in 6/7 chronic pain subjects.[11][5]
- Neuroprotection & Stroke Recovery β DSIP/KND reduced brain infarction volume during reperfusion; accelerated motor function recovery in focal stroke.[8][7]
- Cardioprotection β Reduces myocardial infarction size (IA/AAR 28.7% vs 42.1% control); stabilizes mitochondrial respiration. β οΈ 100% mortality if given during occlusion phase.[8]
- Epilepsy & Anticonvulsant β In the metaphit audiogenic seizure model, DSIP alone did not significantly alter seizure latency, but potentiated the anticonvulsive activity of an otherwise non-protective valproate dose; intranigral DSIP and its analogs have also been studied for effects on movement and convulsive activity.[16][20]
- Geroprotection & Oncology β Maximum lifespan +24.1% in SHR mice; total tumors β2.6-fold; mammary carcinoma β5-fold; chromosomal aberrations β22.6%.[10]
- Mitochondrial & Antioxidant Research β Stabilizes NADH-dehydrogenase, enhances oxidative phosphorylation, stimulates SOD/catalase/glutathione peroxidase β used as a tool peptide for studying mitochondrial cytoprotection under hypoxic/ischemic stress.[9]
- HPA Axis Stress Resistance β Prevents c-Fos induction in paraventricular nucleus, lowers basal corticotropin, increases resistance to acute emotional stress in rodent models (Sudakov 1983, Salieva 1989).[18][21]
Comparative Research Context
DSIP occupies a unique position in the adaptogen / programming-modulator literature alongside other stress-and-circadian-rhythm peptides such as Selank, Semax, Epithalon, and Pinealon. Where Selank acts via tuftsin-related immunomodulatory and anxiolytic pathways and Semax activates BDNF expression in the hippocampus, DSIP appears to operate through state-dependent stabilization of multiple receptor systems without a dedicated high-affinity target. Researchers comparing DSIP with related adaptogen peptides commonly cross-reference our Selank, Semax, and Epithalon pages for parallel preclinical pharmacology β particularly for studies addressing slow-wave sleep, oxidative stress resistance, and HPA-axis modulation in rodent models. The KND peptide and [D-AlaΒ²]DSIP analogs remain the standard tools for distinguishing DSIP-specific effects from generic peptide vehicle effects in mechanism-of-action studies.
βPreclinical Research Summary Key Preclinical Studies StudyModelKey FindingsRef Mu et al.β
References
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): A still unresolved riddle. J Neurochem. 2006;97(2):303-309.
- Dick P, Costa C, Fayolle K, et al. DSIP in the treatment of withdrawal syndromes from alcohol and opiates. Eur Neurol. 1984;23(5):364-371.
- Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA. Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior. Int J Clin Pharmacol Ther Toxicol. 1981;19(8):341-345.
- Schneider-Helmert D. Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. Eur Neurol. 1987;27(2):120-129.
- Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. Eur Neurol. 1984;23(5):372-385.
- Kaeser HE. A clinical trial with DSIP. Eur Neurol. 1984;23(5):386-388.
- Tukhovskaya EA, Ismailova AM, Shaykhutdinova ER, et al. Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules. 2021;26(17):5173.
- Tukhovskaya EA, Shaykhutdinova ER, Ismailova AM, et al. DSIP-Like KND Peptide Reduces Brain Infarction in C57Bl/6 and Reduces Myocardial Infarction in SD Rats When Administered during Reperfusion. Biomedicines. 2021;9(4):407.
- Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984;8(1):83-93.
- Popovich IG, Voitenkov BO, Anisimov VN, et al. Effect of delta-sleep inducing peptide-containing preparation Deltaran on biomarkers of aging, life span and spontaneous tumor incidence in female SHR mice. Mech Ageing Dev. 2003;124(6):721-731.
- Nakamura A, Nakashima M, Sugao T, et al. Potent antinociceptive effect of centrally administered delta-sleep-inducing peptide (DSIP). Eur J Pharmacol. 1988;155(3):247-253.
- Dick P, Grandjean ME, Tissot R. Successful treatment of withdrawal symptoms with delta sleep-inducing peptide. Neuropsychobiology. 1983;10(4):205-208.
- Scherschlicht RR, Tissot R. Nonapeptide for treating addictive drug withdrawal conditions. US Patent 4,444,758. 1984.
- Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA Website. Updated July 2025.
- Schoenenberger GA. Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP). Eur Neurol. 1984;23(5):321-345.
- HrnΔiΔ D, StanojloviΔ O, Ε½ivanoviΔ D, Ε uΕ‘iΔ V. Delta-sleep-inducing peptide potentiates anticonvulsive activity of valproate against metaphit-provoked audiogenic seizure in rats. Pharmacology. 2006;77(2):78-84.
- Monnier M, Dudler L, Gaechter R, et al. The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide. Experientia. 1977;33(4):548-552.
- Sudakov KV, Ivanov VT, Koplik EV, et al. Delta-sleep-inducing peptide (DSIP) as a factor facilitating animals' resistance to acute emotional stress. Pavlov J Biol Sci. 1983;18(1):1-5.
- Graf M, Baumann JB, Girard J, et al. DSIP-induced changes of daily concentrations of brain neurotransmitters and plasma proteins in rats. Pharmacol Biochem Behav. 1982;17(3):511-517.
- Shandra AA, Godlevskii RS, Vast'yanov AI, et al. Effect of intranigral dosage with delta-sleep-inducing peptide and its analogs on movement and convulsive activity in rats. Neurosci Behav Physiol. 1996;26(6):567-571.
- Salieva RM, Koplik EV, Kamenov ZA, Poletaev AB. Effects of beta endorphin and delta-sleep inducing peptide on resistance to emotional stress. Biull Eksp Biol Med. 1989;108(10):464-466.
- Mu X, Qu L, Yin L, Wang L, Liu X, Liu D. Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models. Front Pharmacol. 2024;15:1439536.
- Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193-197.
Related Research Questions
Related research
Want the complete research review?
View Full DSIP Research PageβFOR RESEARCH USE ONLY
This content is provided for educational and informational purposes only. Products are furnished for in-vitro studies only and are not medicines, drugs, or supplements. Not approved by the FDA to prevent, treat, or cure any condition.
